ARTICLE | Company News
Autolus, UCL in CAR T deal
April 27, 2018 7:18 PM UTC
UCL Business plc (London, U.K.) granted Autolus Ltd. (London, U.K.) worldwide rights to develop and commercialize CD19 CAR T cell therapy AUTO1 to treat B cell malignancies.
Autolus said AUTO1 has a binder with an equivalent on-rate and faster off-rate compared with other CD19 CAR therapies, which reduces cytokine release syndrome. CRS is a collection of toxicities that arises when infused T cells expand and cytokines are rapidly released (see BioCentury, April 21, 2014)...